Results 61 to 70 of about 26,727 (247)

Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD

International Journal of COPD, 2015
Sanjeevan Muruganandan,1 Lata Jayaram2,3 1Department of Respiratory and Sleep Medicine, Austin Health, 2Department of Respiratory and Sleep Medicine, Western Health, 3University of Melbourne, Melbourne, Victoria, Australia Abstract: Chronic obstructive
Muruganandan S, Jayaram L
doaj  

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Long-term exposure to muscarinic agonists decreases expression of contractile proteins and responsiveness of rabbit tracheal smooth muscle cells

, 2014
Background: Chronic airway diseases, like asthma or COPD, are characterized by excessive acetylcholine release and airway remodeling. The aim of this study was to investigate the long-term effect of muscarinic agonists on the phenotype and proliferation ...
Stamatiou, R., Mylonis, I., Paschalis Adam Molyvdas, Vasilaki, A., Efrosini Paraskeva, Hatziefthimiou, A., Anna Vasilaki, Molyvdas, P. A., Paraskeva, E., Ilias Mylonis, Rodopi Stamatiou, Konstantinos Gourgoulianis, Apostolia Hatziefthimiou, Gourgoulianis, K.   +13 more
core   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

Therapeutics and Clinical Risk Management, 2014
Jun Zhong, Michael Roth Pneumology and Pulmonary Cell Research, Department of Biomedicine and Internal Medicine, University Hospital Basel, Basel, Switzerland Abstract: Chronic obstructive pulmonary disease (COPD) is increasing worldwide and is ...
Zhong J, Roth M
doaj  

Functional Activation of G-Proteins Coupled With Muscarinic Acetylcholine Receptors in Rat Brain Membranes

Journal of Pharmacological Sciences, 2014
.: The functional activation of Gi/o proteins coupled to muscarinic acetylcholine receptors (mAChRs) was investigated with the conventional guanosine-5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding assay in rat brain membranes.
Yuji Odagaki, Masakazu Kinoshita, Ryoichi Toyoshima   +2 more
doaj   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) CM de Lange   +26 more
wiley   +1 more source

ENANTIO- AND TISSUE-SETECTIVITY OF CHIRAL MUSCARINIC AGONISTS CARRYING A 1.3-OXATHIOLANE NUCLEUS

, 1988
ln order to investigate tissue and enantioserectivity of 1,3-oxathiolane muscarinic agonists we have estimated potency, affinity and relative efficacy according to Furchgott and Bursztyn on isolated preparations of guinea pig ileum, atria and rat urinary
F. Gualtier, E. Teodori, BRASILI, Livio, F. Angeli   +3 more
core  

Are muscarinic agonists and acetylcholinesterase inhibitors effective for the treatment of underactive bladder? [PDF]

, 2023
Introduction & Objectives: There are a range of mechanisms and systems underlying urinary bladder contractions, with interactions between nerves, endogenously released chemicals and receptors all playing a part in the overall function1,2.
Moro, Christian, Phelps, Charlotte, Veer, Vineesha   +2 more
core  

Importance and prospects for design of selective muscarinic agonists

Physiological Research, 2008
There are five subtypes of muscarinic receptors that serve various important physiological functions in the central nervous system and the periphery. Mental functions like attention, learning, and memory are attributed to the muscarinic M1 subtype. These functions decline during natural aging and an early deficit is typical for Alzheimer s disease.
J, Jakubík, P, Michal, E, Machová, V, Dolezal   +3 more
openaire   +2 more sources